Company Description
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States.
Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis.
The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma.
It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas.
The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product.
The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017.
Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Oct 11, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 35 |
| CEO | Bruce Steel |
Contact Details
Address: 2223 Avenida De La Playa, Suite 105 La Jolla, California 92037 United States | |
| Phone | 858 240 1200 |
| Website | equilliumbio.com |
Stock Details
| Ticker Symbol | EQ |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001746466 |
| CUSIP Number | 29446K106 |
| ISIN Number | US29446K1060 |
| Employer ID | 82-1554746 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Bruce D. Steel C.F.A. | Co-Founder, Chief Executive Officer and Director |
| Dr. Stephen Connelly Ph.D. | Chief Scientific Officer and President |
| Christine Zedelmayer M.B.A., P.M.P. | Senior Vice President and Chief Operating Officer |
| Penny Tom | Senior Vice President of Finance and Principal Accounting Officer |
| Michael Moore | Vice President of Investor Relations and Corporate Communications |
| Dr. Lisette Acevedo | Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 25, 2025 | 144 | Filing |
| Nov 14, 2025 | SCHEDULE 13G | Filing |
| Nov 14, 2025 | SCHEDULE 13G | Filing |
| Nov 13, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 13, 2025 | 10-Q | Quarterly Report |
| Nov 13, 2025 | 8-K | Current Report |
| Nov 13, 2025 | SCHEDULE 13G | Filing |
| Oct 24, 2025 | 8-K/A | [Amend] Current report |
| Oct 6, 2025 | 8-K | Current Report |
| Sep 19, 2025 | 8-K | Current Report |